Samotolisib (LY3023414) is an oral ATP competitive inhibitor of the class I PI3K isoforms, DNA-PK, and mTOR. Samotolisib (LY3023414) has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
Molecular Weight:
406.48
Purity:
99.71%
CAS Number:
[1386874-06-1]
Formula:
C23H26N4O3
Target:
mTOR|||Autophagy|||DNA-PK|||PI3K
T6883
* VAT and and shipping costs not included. Errors and price changes excepted